Re-engineered Yeast Glycosylation System Might Replace Mammalian Cell Expression

摘要

Lebanon, NH (Sept 7)-Scientists from GlycoFi, Inc. (www glycofi com), a wholly owned subsidiary ofMerck&Co. (White-house Station, NJ, wwwmerck com), in collaboration with Dartmouth-Hitchcock Medical Center, have engineered yeast cells capable of producing a broad range of recombinant therapeutic proteins with fully human sugar structures (glycosylation). Until now, these sugar structures, which ensure a glycoprotein's biological activity and half-life, required the expression of therapeutic glycoproteins from mammalian host cells